CU20120152A7 - Comprimido de desintegración por vía oral que contiene acarbosa - Google Patents

Comprimido de desintegración por vía oral que contiene acarbosa

Info

Publication number
CU20120152A7
CU20120152A7 CU2012000152A CU20120152A CU20120152A7 CU 20120152 A7 CU20120152 A7 CU 20120152A7 CU 2012000152 A CU2012000152 A CU 2012000152A CU 20120152 A CU20120152 A CU 20120152A CU 20120152 A7 CU20120152 A7 CU 20120152A7
Authority
CU
Cuba
Prior art keywords
compressed
decrease
oral route
route containing
containing acarbose
Prior art date
Application number
CU2012000152A
Other languages
English (en)
Inventor
Axel Schneeweis
Tobias Laich
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20120152A7 publication Critical patent/CU20120152A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Era un objeto de la presente invención proporcionar un comprimido de desintegración por vía oral (ODT) para el inhibidor de la glucosidasa acarbosa. El objetivo se consigue con un comprimido de desintegración por vía oral que contiene un 1-30 % de acarboza y un 40-90 % de vehículo soluble en agua. Con el fin de obtener las propiedades deseadas, se tienen que compactar previamente los ingredientes y mezclar previamente con un vehículo insoluble.
CU2012000152A 2010-04-27 2012-10-25 Comprimido de desintegración por vía oral que contiene acarbosa CU20120152A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161114 2010-04-27
PCT/EP2011/056587 WO2011134962A2 (en) 2010-04-27 2011-04-26 Orally disintegrating tablet containing acarbose

Publications (1)

Publication Number Publication Date
CU20120152A7 true CU20120152A7 (es) 2014-02-28

Family

ID=44344015

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000152A CU20120152A7 (es) 2010-04-27 2012-10-25 Comprimido de desintegración por vía oral que contiene acarbosa

Country Status (27)

Country Link
US (1) US20130131003A1 (es)
EP (1) EP2563329B1 (es)
JP (1) JP5944378B2 (es)
KR (1) KR101788350B1 (es)
CN (2) CN106924199A (es)
AU (1) AU2011247642C1 (es)
BR (1) BR112012027303A2 (es)
CA (1) CA2797365A1 (es)
CL (1) CL2012003011A1 (es)
CO (1) CO6640213A2 (es)
CR (1) CR20120548A (es)
CU (1) CU20120152A7 (es)
DO (1) DOP2012000277A (es)
EC (1) ECSP12012279A (es)
ES (1) ES2623025T3 (es)
GT (1) GT201200290A (es)
IL (1) IL222368B (es)
MX (1) MX348865B (es)
MY (1) MY179724A (es)
NZ (1) NZ603199A (es)
PE (1) PE20130403A1 (es)
PH (1) PH12012502139A1 (es)
SG (2) SG184851A1 (es)
SI (1) SI2563329T1 (es)
TW (1) TWI556823B (es)
UA (1) UA111155C2 (es)
WO (1) WO2011134962A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201100150A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Suda çözünür dozaj formları
WO2013115741A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical compositions comprising alpha-glucosidase inhibitor
WO2013115738A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Micronized acarbose
EP2890370B1 (en) * 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN104013590A (zh) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 一种含阿卡波糖的药物组合物及其制备方法
KR101937069B1 (ko) * 2014-12-17 2019-04-03 엠프로스 파마 악티에볼라그 비만 및 관련 대사 장애의 치료를 위한 오를리스타트 및 아카르보스의 변형 방출형 조성물
CN105213341A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种阿卡波糖片及其制备方法
CN113081984B (zh) * 2021-04-19 2023-06-02 北京阳光诺和药物研究股份有限公司 一种阿卡波糖口崩片及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPH10182687A (ja) * 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
KR100682836B1 (ko) * 2004-12-06 2007-02-15 엘지전자 주식회사 유기 전계 발광 소자
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
MY157620A (en) * 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
JP4931907B2 (ja) * 2006-02-27 2012-05-16 パナソニック株式会社 ウェアラブル端末、および、携帯撮像収音装置、およびそれらを実現する装置、方法、プログラム
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN101411715B (zh) * 2007-10-19 2012-03-28 杭州华东医药集团生物工程研究所有限公司 含有阿卡波糖的药物组合物
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
WO2009071219A2 (en) * 2007-12-08 2009-06-11 Bayer Schering Pharma Aktiengesellschaft Oral dispersable tablet
AR069875A1 (es) * 2007-12-21 2010-02-24 Eurand Inc Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido

Also Published As

Publication number Publication date
SI2563329T1 (sl) 2017-05-31
CO6640213A2 (es) 2013-03-22
TWI556823B (zh) 2016-11-11
UA111155C2 (uk) 2016-04-11
IL222368A0 (en) 2012-12-31
AU2011247642B2 (en) 2015-05-14
EP2563329A2 (en) 2013-03-06
SG10201505844WA (en) 2015-09-29
WO2011134962A2 (en) 2011-11-03
MX2012012459A (es) 2012-11-21
AU2011247642A1 (en) 2012-11-08
KR101788350B1 (ko) 2017-10-19
WO2011134962A3 (en) 2012-05-03
JP5944378B2 (ja) 2016-07-05
CL2012003011A1 (es) 2013-04-19
DOP2012000277A (es) 2012-12-15
GT201200290A (es) 2014-09-24
CN102905687A (zh) 2013-01-30
IL222368B (en) 2018-11-29
PE20130403A1 (es) 2013-04-13
BR112012027303A2 (pt) 2017-10-24
CN106924199A (zh) 2017-07-07
US20130131003A1 (en) 2013-05-23
ECSP12012279A (es) 2012-11-30
ES2623025T3 (es) 2017-07-10
KR20130062926A (ko) 2013-06-13
JP2013525404A (ja) 2013-06-20
TW201141490A (en) 2011-12-01
CR20120548A (es) 2013-03-11
EP2563329B1 (en) 2017-04-12
SG184851A1 (en) 2012-11-29
PH12012502139A1 (en) 2022-03-21
CA2797365A1 (en) 2011-11-03
MX348865B (es) 2017-07-03
NZ603199A (en) 2014-05-30
MY179724A (en) 2020-11-11
AU2011247642C1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
ECSP12012279A (es) Comprimido de desintegración por vía oral que contiene acarbosa
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CL2016001547A1 (es) Composiciones para el cuidado oral
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
ECSP13012715A (es) Método para producir preparados farmacéuticos con contenido de ibp
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
MX2014008457A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
GT201200165A (es) Triazolopiridinas
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
CL2016000510A1 (es) Composiciones para comprimidos bucodispersables que contienen corticosteroides para esofagitis eosinofílica
ECSP13012667A (es) Compuestos de triazolopiridina
PE20151979A1 (es) Compuestos quimicos
WO2012141971A3 (en) Methods and compositions for rejuvenation and expansion of stem cells
BR112015008912A2 (pt) composições solidificáveis compreendendo volastonita e pedra-pomes e métodos de uso
TR201907136T4 (tr) Fertigasyon bileşimi ve fertigasyona yönelik yöntem.
CO7091174A2 (es) Compuestos triazolo como inhibidores de pde10
PE20161228A1 (es) Composiciones y metodos que se relacionan a un hidrogel de polimero oclusivo
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
AR089114A1 (es) PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
NI201300100A (es) Derivados de tieno [2, 3-d] pirimidina y su uso para tratar arritmias
MX2016001303A (es) Composiciones farmaceuticas de ranolazina y dronedarona.
MX2015006054A (es) Enemas.
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida